Nippon Kayaku To Commence Phase I For Spectrum's Bladder Cancer Drug
This article was originally published in PharmAsia News
Nippon Kayaku plans to start a Japanese domestic phase I study for apaziquone within the year, aiming for a market launch in 2015
You may also be interested in...
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
La Jolla’s formulation appears blocked by Amivas’ seven-year orphan exclusivity, and the company also will miss out on chance for a tropical disease priority review voucher; Amivas worked with the US Army to bring the severe malaria treatment through final stages of development and regulatory review.